Allogene CEO David Chang and new head of R&D Zachary Roberts
January 3, 2023 08:00 AM ESTUpdated 08:48 AM
Bioregnum
R&D

Up­dat­ed: Off-the-shelf cell ther­a­py pi­o­neer Al­lo­gene re­cruits a Kite vet to run R&D

Af­ter rid­ing out much of a rough year at In­stil Bio — capped by a de­ci­sion to pause and then scrap the lead tu­mor-in­fil­trat­ing lym­pho­cyte pro­gram …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times